|
Market Closed -
Australian S.E.
08:12:42 09/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 183.84 AUD | +1.31% |
|
+4.84% | +6.48% |
| 10-09 | CSL to Transition US Plasma Centers to Haemonetics' Latest Plasmapheresis Platform | MT |
| 10-08 | Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027 | DJ |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 61.44B | |||||
| 1,051B | |||||
| 630B | - | ||||
| 489B | |||||
| 359B | |||||
| 344B |
- Stock Market
- Stocks
- CSL Stock
- Charts CSL Limited
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
